View ValuationThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsShedir Pharma Group 将来の成長Future 基準チェック /36Shedir Pharma Group利益と収益がそれぞれ年間7.9%と6.3%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に12.7% 7.8%なると予測されています。主要情報7.9%収益成長率7.75%EPS成長率Pharmaceuticals 収益成長10.7%収益成長率6.3%将来の株主資本利益率12.65%アナリストカバレッジLow最終更新日15 Oct 2024今後の成長に関する最新情報Major Estimate Revision • Apr 12Consensus EPS estimates increase by 10%The consensus outlook for earnings per share (EPS) in fiscal year 2023 has improved. 2023 revenue forecast increased from €56.5m to €57.5m. EPS estimate increased from €0.50 to €0.55 per share. Net income forecast to grow 37% next year vs 17% growth forecast for Pharmaceuticals industry in Italy. Consensus price target up from €7.62 to €7.93. Share price rose 6.8% to €4.38 over the past week.Price Target Changed • May 21Price target decreased to €5.20Down from €6.00, the current price target is an average from 2 analysts. New target price is 22% above last closing price of €4.26. Stock is up 5.4% over the past year.Price Target Changed • Oct 24Price target lowered to €6.95Down from €7.53, the current price target is an average from 2 analysts. The new target price is 64% above the current share price of €4.23. As of last close, the stock is down 43% over the past year.すべての更新を表示Recent updates分析記事 • Nov 08Shedir Pharma Group S.p.A.'s (BIT:SHE) Share Price Boosted 25% But Its Business Prospects Need A Lift TooShedir Pharma Group S.p.A. ( BIT:SHE ) shareholders have had their patience rewarded with a 25% share price jump in the...New Risk • Nov 08New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Italian stocks, typically moving 3.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (3.6% average weekly change). Market cap is less than US$100m (€47.0m market cap, or US$50.6m).Valuation Update With 7 Day Price Move • Nov 07Investor sentiment improves as stock rises 25%After last week's 25% share price gain to €4.84, the stock trades at a forward P/E ratio of 8x. Average forward P/E is 14x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 13% over the past three years.Reported Earnings • Sep 29First half 2024 earnings released: EPS: €0.14 (vs €0.10 in 1H 2023)First half 2024 results: EPS: €0.14 (up from €0.10 in 1H 2023). Revenue: €29.8m (up 5.5% from 1H 2023). Net income: €1.56m (up 32% from 1H 2023). Profit margin: 5.2% (up from 4.2% in 1H 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.Buy Or Sell Opportunity • Sep 09Now 22% overvaluedOver the last 90 days, the stock has fallen 1.5% to €3.92. The fair value is estimated to be €3.22, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Earnings per share has grown by 20%.Buy Or Sell Opportunity • Aug 02Now 20% overvalued after recent price riseOver the last 90 days, the stock has risen 4.9% to €3.86. The fair value is estimated to be €3.22, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Earnings per share has grown by 20%.分析記事 • Apr 05Shedir Pharma Group's (BIT:SHE) Sluggish Earnings Might Be Just The Beginning Of Its ProblemsInvestors were disappointed by Shedir Pharma Group S.p.A.'s ( BIT:SHE ) latest earnings release. We did some further...Valuation Update With 7 Day Price Move • Feb 13Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to €3.78, the stock trades at a forward P/E ratio of 7x. Average forward P/E is 13x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 23% over the past three years.Upcoming Dividend • May 01Upcoming dividend of €0.17 per share at 3.4% yieldEligible shareholders must have bought the stock before 08 May 2023. Payment date: 10 May 2023. Trailing yield: 3.4%. Lower than top quartile of Italian dividend payers (5.1%). Higher than average of industry peers (2.5%).Upcoming Dividend • Apr 25Upcoming dividend of €0.17 per share at 3.5% yieldEligible shareholders must have bought the stock before 02 May 2023. Payment date: 04 May 2023. Trailing yield: 3.5%. Lower than top quartile of Italian dividend payers (5.1%). Higher than average of industry peers (2.5%).Valuation Update With 7 Day Price Move • Apr 20Investor sentiment improves as stock rises 16%After last week's 16% share price gain to €5.00, the stock trades at a forward P/E ratio of 9x. Average forward P/E is 17x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 13% over the past three years.Major Estimate Revision • Apr 12Consensus EPS estimates increase by 10%The consensus outlook for earnings per share (EPS) in fiscal year 2023 has improved. 2023 revenue forecast increased from €56.5m to €57.5m. EPS estimate increased from €0.50 to €0.55 per share. Net income forecast to grow 37% next year vs 17% growth forecast for Pharmaceuticals industry in Italy. Consensus price target up from €7.62 to €7.93. Share price rose 6.8% to €4.38 over the past week.Valuation Update With 7 Day Price Move • Apr 06Investor sentiment improves as stock rises 16%After last week's 16% share price gain to €4.28, the stock trades at a forward P/E ratio of 9x. Average forward P/E is 17x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 36% over the past three years.Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. No highly experienced directors. 1 independent director (4 non-independent directors). Independent Director Marco Mazzarese was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • Oct 03First half 2022 earnings released: EPS: €0 (vs €0.06 in 1H 2021)First half 2022 results: EPS: €0. Revenue: €23.8m (up 26% from 1H 2021). Net income: €987.0k (up 45% from 1H 2021). Profit margin: 4.2% (up from 3.6% in 1H 2021). The increase in margin was driven by higher revenue.Valuation Update With 7 Day Price Move • Jul 12Investor sentiment improved over the past weekAfter last week's 18% share price gain to €3.30, the stock trades at a forward P/E ratio of 8x. Average forward P/E is 20x in the Pharmaceuticals industry in Europe. Total loss to shareholders of 17% over the past year.Upcoming Dividend • May 02Upcoming dividend of €0.13 per shareEligible shareholders must have bought the stock before 09 May 2022. Payment date: 11 May 2022. Payout ratio is a comfortable 38% and this is well supported by cash flows. Trailing yield: 3.4%. Lower than top quartile of Italian dividend payers (4.7%). Higher than average of industry peers (2.5%).Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Director Marco Mazzarese was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Apr 19Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2021 results: EPS: €0.34 (vs €0.34 in FY 2020). Revenue: €44.8m (up 3.8% from FY 2020). Net income: €3.93m (flat on FY 2020). Profit margin: 8.8% (down from 9.1% in FY 2020). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 2.5%. Earnings per share (EPS) missed analyst estimates by 1.7%. Over the next year, revenue is forecast to grow 9.7%, compared to a 7.0% growth forecast for the pharmaceuticals industry in Italy.分析記事 • Oct 05Why Shedir Pharma Group's (BIT:SHE) Earnings Are Better Than They SeemShedir Pharma Group S.p.A.'s ( BIT:SHE ) solid earnings announcement recently didn't do much to the stock price. We did...Reported Earnings • Oct 03First half 2021 earnings releasedThe company reported a poor first half result with weaker earnings, revenues and profit margins. First half 2021 results: Revenue: €18.5m (down 3.5% from 1H 2020). Net income: €681.0k (down 42% from 1H 2020). Profit margin: 3.7% (down from 6.1% in 1H 2020). The decrease in margin was driven by lower revenue.Valuation Update With 7 Day Price Move • Sep 13Investor sentiment improved over the past weekAfter last week's 17% share price gain to €4.92, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 25x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 28% over the past year.Price Target Changed • May 21Price target decreased to €5.20Down from €6.00, the current price target is an average from 2 analysts. New target price is 22% above last closing price of €4.26. Stock is up 5.4% over the past year.分析記事 • Apr 06Is Shedir Pharma Group (BIT:SHE) Using Too Much Debt?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Is New 90 Day High Low • Feb 04New 90-day low: €3.42The company is down 25% from its price of €4.55 on 05 November 2020. The Italian market is up 14% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is flat over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €9.14 per share.Is New 90 Day High Low • Jan 18New 90-day low: €3.54The company is down 12% from its price of €4.04 on 20 October 2020. The Italian market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €9.18 per share.分析記事 • Dec 30What Type Of Returns Would Shedir Pharma Group's(BIT:SHE) Shareholders Have Earned If They Purchased Their SharesYear Ago?Passive investing in an index fund is a good way to ensure your own returns roughly match the overall market. Active...Is New 90 Day High Low • Dec 01New 90-day low: €3.72The company is down 10.0% from its price of €4.14 on 01 September 2020. The Italian market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €7.93 per share.Is New 90 Day High Low • Oct 26New 90-day high: €4.39The company is up 6.0% from its price of €4.14 on 28 July 2020. The Italian market is down 4.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €9.90 per share.Price Target Changed • Oct 24Price target lowered to €6.95Down from €7.53, the current price target is an average from 2 analysts. The new target price is 64% above the current share price of €4.23. As of last close, the stock is down 43% over the past year.Is New 90 Day High Low • Oct 02New 90-day low: €3.97The company is down 14% from its price of €4.59 on 03 July 2020. The Italian market is down 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 4.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €9.64 per share.業績と収益の成長予測BIT:SHE - アナリストの将来予測と過去の財務データ ( )EUR Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20277681013112/31/20267271012112/31/2025687811112/31/202464691116/30/202461669N/A3/31/202460615N/A12/31/2023596-41N/A9/30/2023596-30N/A6/30/2023586-20N/A3/31/202356601N/A12/31/202253613N/A9/30/202251557N/A6/30/20224941011N/A3/31/20224741012N/A12/31/20214541012N/A9/30/2021444810N/A6/30/202143379N/A3/31/202143489N/A12/31/2020434910N/A9/30/202044357N/A6/30/202045313N/A3/31/2020473-4-1N/A12/31/2019513-5-3N/A9/30/2019504-3-1N/A6/30/2019495-10N/A3/31/201949667N/A12/31/2018477-3-1N/A12/31/2017403N/A5N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: SHEの予測収益成長率 (年間7.9% ) は 貯蓄率 ( 2.5% ) を上回っています。収益対市場: SHEの収益 ( 7.9% ) はItalian市場 ( 11.2% ) よりも速いペースで成長すると予測されています。高成長収益: SHEの収益は増加すると予測されていますが、大幅には増加しません。収益対市場: SHEの収益 ( 6.3% ) Italian市場 ( 5.8% ) よりも速いペースで成長すると予測されています。高い収益成長: SHEの収益 ( 6.3% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: SHEの 自己資本利益率 は、3年後には低くなると予測されています ( 12.7 %)。成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2025/01/24 07:48終値2025/01/22 00:00収益2024/06/30年間収益2023/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Shedir Pharma Group S.p.A. 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Gian GadiniBanca Akros S.p.A. (ESN)Maria Di GradoKT & Partners Srl
Major Estimate Revision • Apr 12Consensus EPS estimates increase by 10%The consensus outlook for earnings per share (EPS) in fiscal year 2023 has improved. 2023 revenue forecast increased from €56.5m to €57.5m. EPS estimate increased from €0.50 to €0.55 per share. Net income forecast to grow 37% next year vs 17% growth forecast for Pharmaceuticals industry in Italy. Consensus price target up from €7.62 to €7.93. Share price rose 6.8% to €4.38 over the past week.
Price Target Changed • May 21Price target decreased to €5.20Down from €6.00, the current price target is an average from 2 analysts. New target price is 22% above last closing price of €4.26. Stock is up 5.4% over the past year.
Price Target Changed • Oct 24Price target lowered to €6.95Down from €7.53, the current price target is an average from 2 analysts. The new target price is 64% above the current share price of €4.23. As of last close, the stock is down 43% over the past year.
分析記事 • Nov 08Shedir Pharma Group S.p.A.'s (BIT:SHE) Share Price Boosted 25% But Its Business Prospects Need A Lift TooShedir Pharma Group S.p.A. ( BIT:SHE ) shareholders have had their patience rewarded with a 25% share price jump in the...
New Risk • Nov 08New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Italian stocks, typically moving 3.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (3.6% average weekly change). Market cap is less than US$100m (€47.0m market cap, or US$50.6m).
Valuation Update With 7 Day Price Move • Nov 07Investor sentiment improves as stock rises 25%After last week's 25% share price gain to €4.84, the stock trades at a forward P/E ratio of 8x. Average forward P/E is 14x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 13% over the past three years.
Reported Earnings • Sep 29First half 2024 earnings released: EPS: €0.14 (vs €0.10 in 1H 2023)First half 2024 results: EPS: €0.14 (up from €0.10 in 1H 2023). Revenue: €29.8m (up 5.5% from 1H 2023). Net income: €1.56m (up 32% from 1H 2023). Profit margin: 5.2% (up from 4.2% in 1H 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.
Buy Or Sell Opportunity • Sep 09Now 22% overvaluedOver the last 90 days, the stock has fallen 1.5% to €3.92. The fair value is estimated to be €3.22, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Earnings per share has grown by 20%.
Buy Or Sell Opportunity • Aug 02Now 20% overvalued after recent price riseOver the last 90 days, the stock has risen 4.9% to €3.86. The fair value is estimated to be €3.22, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Earnings per share has grown by 20%.
分析記事 • Apr 05Shedir Pharma Group's (BIT:SHE) Sluggish Earnings Might Be Just The Beginning Of Its ProblemsInvestors were disappointed by Shedir Pharma Group S.p.A.'s ( BIT:SHE ) latest earnings release. We did some further...
Valuation Update With 7 Day Price Move • Feb 13Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to €3.78, the stock trades at a forward P/E ratio of 7x. Average forward P/E is 13x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 23% over the past three years.
Upcoming Dividend • May 01Upcoming dividend of €0.17 per share at 3.4% yieldEligible shareholders must have bought the stock before 08 May 2023. Payment date: 10 May 2023. Trailing yield: 3.4%. Lower than top quartile of Italian dividend payers (5.1%). Higher than average of industry peers (2.5%).
Upcoming Dividend • Apr 25Upcoming dividend of €0.17 per share at 3.5% yieldEligible shareholders must have bought the stock before 02 May 2023. Payment date: 04 May 2023. Trailing yield: 3.5%. Lower than top quartile of Italian dividend payers (5.1%). Higher than average of industry peers (2.5%).
Valuation Update With 7 Day Price Move • Apr 20Investor sentiment improves as stock rises 16%After last week's 16% share price gain to €5.00, the stock trades at a forward P/E ratio of 9x. Average forward P/E is 17x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 13% over the past three years.
Major Estimate Revision • Apr 12Consensus EPS estimates increase by 10%The consensus outlook for earnings per share (EPS) in fiscal year 2023 has improved. 2023 revenue forecast increased from €56.5m to €57.5m. EPS estimate increased from €0.50 to €0.55 per share. Net income forecast to grow 37% next year vs 17% growth forecast for Pharmaceuticals industry in Italy. Consensus price target up from €7.62 to €7.93. Share price rose 6.8% to €4.38 over the past week.
Valuation Update With 7 Day Price Move • Apr 06Investor sentiment improves as stock rises 16%After last week's 16% share price gain to €4.28, the stock trades at a forward P/E ratio of 9x. Average forward P/E is 17x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 36% over the past three years.
Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. No highly experienced directors. 1 independent director (4 non-independent directors). Independent Director Marco Mazzarese was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • Oct 03First half 2022 earnings released: EPS: €0 (vs €0.06 in 1H 2021)First half 2022 results: EPS: €0. Revenue: €23.8m (up 26% from 1H 2021). Net income: €987.0k (up 45% from 1H 2021). Profit margin: 4.2% (up from 3.6% in 1H 2021). The increase in margin was driven by higher revenue.
Valuation Update With 7 Day Price Move • Jul 12Investor sentiment improved over the past weekAfter last week's 18% share price gain to €3.30, the stock trades at a forward P/E ratio of 8x. Average forward P/E is 20x in the Pharmaceuticals industry in Europe. Total loss to shareholders of 17% over the past year.
Upcoming Dividend • May 02Upcoming dividend of €0.13 per shareEligible shareholders must have bought the stock before 09 May 2022. Payment date: 11 May 2022. Payout ratio is a comfortable 38% and this is well supported by cash flows. Trailing yield: 3.4%. Lower than top quartile of Italian dividend payers (4.7%). Higher than average of industry peers (2.5%).
Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Director Marco Mazzarese was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Apr 19Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2021 results: EPS: €0.34 (vs €0.34 in FY 2020). Revenue: €44.8m (up 3.8% from FY 2020). Net income: €3.93m (flat on FY 2020). Profit margin: 8.8% (down from 9.1% in FY 2020). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 2.5%. Earnings per share (EPS) missed analyst estimates by 1.7%. Over the next year, revenue is forecast to grow 9.7%, compared to a 7.0% growth forecast for the pharmaceuticals industry in Italy.
分析記事 • Oct 05Why Shedir Pharma Group's (BIT:SHE) Earnings Are Better Than They SeemShedir Pharma Group S.p.A.'s ( BIT:SHE ) solid earnings announcement recently didn't do much to the stock price. We did...
Reported Earnings • Oct 03First half 2021 earnings releasedThe company reported a poor first half result with weaker earnings, revenues and profit margins. First half 2021 results: Revenue: €18.5m (down 3.5% from 1H 2020). Net income: €681.0k (down 42% from 1H 2020). Profit margin: 3.7% (down from 6.1% in 1H 2020). The decrease in margin was driven by lower revenue.
Valuation Update With 7 Day Price Move • Sep 13Investor sentiment improved over the past weekAfter last week's 17% share price gain to €4.92, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 25x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 28% over the past year.
Price Target Changed • May 21Price target decreased to €5.20Down from €6.00, the current price target is an average from 2 analysts. New target price is 22% above last closing price of €4.26. Stock is up 5.4% over the past year.
分析記事 • Apr 06Is Shedir Pharma Group (BIT:SHE) Using Too Much Debt?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Is New 90 Day High Low • Feb 04New 90-day low: €3.42The company is down 25% from its price of €4.55 on 05 November 2020. The Italian market is up 14% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is flat over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €9.14 per share.
Is New 90 Day High Low • Jan 18New 90-day low: €3.54The company is down 12% from its price of €4.04 on 20 October 2020. The Italian market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €9.18 per share.
分析記事 • Dec 30What Type Of Returns Would Shedir Pharma Group's(BIT:SHE) Shareholders Have Earned If They Purchased Their SharesYear Ago?Passive investing in an index fund is a good way to ensure your own returns roughly match the overall market. Active...
Is New 90 Day High Low • Dec 01New 90-day low: €3.72The company is down 10.0% from its price of €4.14 on 01 September 2020. The Italian market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €7.93 per share.
Is New 90 Day High Low • Oct 26New 90-day high: €4.39The company is up 6.0% from its price of €4.14 on 28 July 2020. The Italian market is down 4.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €9.90 per share.
Price Target Changed • Oct 24Price target lowered to €6.95Down from €7.53, the current price target is an average from 2 analysts. The new target price is 64% above the current share price of €4.23. As of last close, the stock is down 43% over the past year.
Is New 90 Day High Low • Oct 02New 90-day low: €3.97The company is down 14% from its price of €4.59 on 03 July 2020. The Italian market is down 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 4.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €9.64 per share.